Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China

ConclusionFrom the perspective of the Chinese healthcare system,CYP2D6*10 pharmacogenetic testing was cost effective for postmenopausal women with ER-positive early breast cancer.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research